Comparative GLP-1 and GIP Weight-Loss Evidence Quiz

Q1. In the reviewed evidence, which drug generally produced greater average weight loss?
- Semaglutide
- Tirzepatide
- Exenatide
- Liraglutide
Answer: Tirzepatide
Q2. Which study-design issue most strongly limits confidence in the semaglutide versus tirzepatide comparison?
- The comparison came entirely from direct randomized head-to-head trials
- Heterogeneity prevented meta-analysis and direct head-to-head randomized trials were scarce
- Follow-up was always longer than 5 years
- Only one drug had any gastrointestinal adverse events
Answer: Heterogeneity prevented meta-analysis and direct head-to-head randomized trials were scarce
Q3. Which adverse events were most commonly reported with these agents in the trials?
- Rash, arthralgia, and insomnia
- Nausea, vomiting, diarrhea, and constipation
- Hair loss and tinnitus
- Hypertension and bradycardia
Answer: Nausea, vomiting, diarrhea, and constipation
Q4. What is the best evidence-based caveat about long-term follow-up in the reviewed literature?
- Most studies followed participants for several years, so durability is well established
- Treatment durations ranged from 16 to 104 weeks, with a median of 43 weeks in one review, and most studies were relatively short
- Long-term follow-up was unnecessary because outcomes were identical across studies
- No study reported any follow-up length
Answer: Treatment durations ranged from 16 to 104 weeks, with a median of 43 weeks in one review, and most studies were relatively short
Q5. What does the evidence suggest about heterogeneity of treatment effects?
- There were no subgroup differences reported anywhere
- Subgroup data suggested possible differences, but one review said the data were insufficient for stratified analyses
- Only patients with diabetes were studied, so heterogeneity could not be assessed
- All studies found identical effects across every subgroup
Answer: Subgroup data suggested possible differences, but one review said the data were insufficient for stratified analyses

nausea, vomiting, diarrhea, and constipation

insufficient to support stratified analyses

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials

Comparative GLP-1 and GIP Weight-Loss Evidence Quiz

Explorer des sujets liés